Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lixte Biotechnology Holdings (LIXT) Change in Accured Expenses (2016)

Lixte Biotechnology Holdings' Change in Accured Expenses history spans 7 years, with the latest figure at $47488.0 for Q4 2016.

  • For Q4 2016, Change in Accured Expenses changed N/A year-over-year to $47488.0; the TTM value through Dec 2016 reached $519.0, changed N/A, while the annual FY2025 figure was $380776.0, 617.7% up from the prior year.
  • Change in Accured Expenses reached $47488.0 in Q4 2016 per LIXT's latest filing, up from $34601.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $107774.0 in Q4 2013 to a low of -$75673.0 in Q1 2016.
  • Average Change in Accured Expenses over 5 years is $26079.8, with a median of $38878.5 recorded in 2015.
  • The largest YoY upside for Change in Accured Expenses was 81.53% in 2016 against a maximum downside of 501.77% in 2016.
  • A 5-year view of Change in Accured Expenses shows it stood at $80416.0 in 2012, then surged by 34.02% to $107774.0 in 2013, then plummeted by 124.82% to -$26749.0 in 2014, then surged by 261.34% to $43156.0 in 2015, then rose by 10.04% to $47488.0 in 2016.
  • Per Business Quant, the three most recent readings for LIXT's Change in Accured Expenses are $47488.0 (Q4 2016), $34601.0 (Q3 2016), and -$5897.0 (Q2 2016).